People: Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

63.70USD
18 Jun 2013
Price Change (% chg)

$1.36 (+2.18%)
Prev Close
$62.34
Open
$62.68
Day's High
$64.69
Day's Low
$60.71
Volume
934,286
Avg. Vol
675,989
52-wk High
$75.69
52-wk Low
$12.86

Search Stocks

Sumeray, Mark 

Brief Biography

Dr. Mark Sumeray, MD, MS, FRCS, has been appointed as Chief Medical Officer of Aegerion Pharmaceuticals, Inc., since August 2011. From November 2009 to July 2011, Dr. Sumeray served as Vice President, Cardiovascular/Metabolics U.S. Medical at Bristol-Myers Squibb, a pharmaceutical company. From December 2004 to November 2009, Dr. Sumeray held various positions at The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President, Medical Business Development, and Vice President Clinical Development and Head of Medical Science. From September 2000 to October 2004, Dr. Sumeray served as worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson. Dr. Sumeray received his B.Sc. degree in Physiology, his M.B.B.S. in medicine, and his M.D. in medicine, each from the University College London. Dr. Sumeray is a Fellow of the Royal College of Surgeons (FRCS) in the United Kingdom.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
239,722 -- 1,758,410 1,998,130

Options Compensation

  Quantity Market Value
Excercisable -- --
Unexercisable -- --
Excercised -- --
Name Fiscal Year Total

David Scheer

--

Marc Beer

2,131,520

Mark Fitzpatrick

3,083,000

Anne Cook

--

Martha Carter

2,002,280

Mark Sumeray

1,998,130
As Of 30 Dec 2011
Search Stocks